

# Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY  
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090

**Natraj**

Ref. :

Date :

NPL/SE/2019

27<sup>th</sup> May, 2019

Online filing at [www.listing.bseindia.com](http://www.listing.bseindia.com)

To,  
The General Manager  
DCS-CRD  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
MUMBAI - 400001

**BSE CODE: 530119**

**Subject: Submission of the Standalone Audited Financial Results along with Auditors' Report thereon for the Quarter/Year ended 31<sup>st</sup> March, 2019 as per Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.**

Dear Sir/Ma'am,

This is in continuation of our letter no. NPL/SE/2019 dated 13<sup>th</sup> May, 2019 regarding intimation for Board meeting for consideration and approval of the Quarterly/Yearly Audited Financial Results for the quarter/ year ended 31<sup>st</sup> March, 2019.

Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Standalone Audited Financial Results along with Auditors' Report thereon by Statutory Auditors for the Quarter/Year ended on 31<sup>st</sup> March, 2019, in PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on 27<sup>th</sup> May, 2019.

Since, the Auditor's Report is self-explanatory and has no modification/qualification, it needs no further comments by the Company.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company [www.natrajproteins.com](http://www.natrajproteins.com).

The Standalone Audited Financial Results will also be published in widely circulated Hindi (Vernacular) and English Newspaper in the prescribed format for that purpose.

You are requested to take on record the Standalone Audited Financial Results along with Auditor's Report for your reference and record.

Thanking You,  
Yours Faithfully,  
For, NATRAJ PROTEINS LTD.

  
KAILASH CHAND SHARMA  
MANAGING DIRECTOR  
DIN: 00012900



Encl.: Auditors' Report along with Audited Financial Results



**ANUP SHRIVASTAVA & CO.  
CHARTERED ACCOUNTANTS**

When an Unmodified Opinion is expressed on the Quarterly financial results for companies (other than banks and insurance companies) - Audited standalone quarterly and year to date

**Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**TO, THE BOARD OF DIRECTORS OF  
NATRAJ PROTEINS LTD, ITARSI**

We have audited the quarterly financial results of NATRAJ PROTEINS LIMITED, ITARSI for the quarter ended 31st March 2019 and the year to date results for the period 01 April 2018 to 31st March 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view of the net profit and other financial information for the quarter ended 31st March 2019 as well as the year to date results for the period from 01 April 2018 to 31st March 2019,

For M/s Anup Shrivastava & Associates  
Chartered Accountants

  
CA. Sudeep Motra  
(Partner)

M No.: 400340  
FRN: 006455C

Place: BHOPAL

Date: 27.05.2019

# NATRAJ PROTEINS LIMITED

CIN: L00153MP1990PLC006090

Regd. Off. - Nagpur Kalan, Ordinance Factory Road, Itarsi, (M.P.)-461111

Email: natrajprotein@rediffmail.com

## Statement of Standalone Audited Financial Results for the quarter and Year ended on 31<sup>st</sup> March, 2019

S. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Previous year ended
		31/03/2019 (Audited)	31/12/2018 (Unaudited)	31/03/2018 (Audited)	31/03/2019 (Audited)	31/03/2018 (Audited)
	(Refer Notes Below)					
I	Income/Revenue from Operations	3873.47	7880.74	4683.40	19072.32	19555.25
II	Other Income	16.15	1.10	0.35	21.28	23.19
III	<b>Total Income (I+II)</b>	<b>3889.62</b>	<b>7881.84</b>	<b>4683.75</b>	<b>19093.60</b>	<b>19578.44</b>
IV	<b>Expenses</b>					
a	Cost of Materials consumed	3509.60	7529.80	2754.34	16692.35	13456.78
b	Purchase of stock-in-trade	257.59	264.36	848.48	824.48	3741.81
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(296.70)	(439.54)	85.82	(210.66)	(16.69)
d	Employee benefits expense	26.42	40.57	32.18	124.60	124.07
e	Finance Costs	66.69	60.67	168.51	420.81	427.37
f	Depreciation and amortization expense	16.89	22.21	19.48	65.03	59.92
g	Other expenses	223.72	380.22	658.99	1041.66	1605.29
h	Excise Duty on Sales	-	-	-	-	1.60
	<b>Total Expenses (IV)</b>	<b>3804.21</b>	<b>7858.29</b>	<b>4567.79</b>	<b>18958.27</b>	<b>19400.15</b>
V	<b>Profit / (Loss) before exceptional items and Tax (I-IV)</b>	<b>85.41</b>	<b>23.55</b>	<b>115.96</b>	<b>135.33</b>	<b>178.29</b>
VI	Exceptional Items	-	-	-	-	-
VII	<b>Profit / (Loss) before tax (V-VI)</b>	<b>85.41</b>	<b>23.55</b>	<b>115.96</b>	<b>135.33</b>	<b>178.29</b>
VIII	Tax expense					
(1)	Current Tax	13.38	7.35	8.33	27.86	23.33
(2)	Deferred Tax	(7.19)	-	(5.60)	(7.19)	(5.60)
IX	<b>Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>80.32</b>	<b>16.20</b>	<b>113.23</b>	<b>114.66</b>	<b>160.56</b>
X	Profit / (Loss) from Discontinuing operations	-	-	-	-	-
XI	Tax expenses from Discontinuing operations	-	-	-	-	-
XII	<b>Profit / (Loss) from Discontinuing operations (after Tax) (X-XI)</b>					
XIII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>80.32</b>	<b>16.20</b>	<b>113.23</b>	<b>114.66</b>	<b>160.56</b>
XIV	Other Comprehensive Income: A (i) Items that will not be reclassified to Profit or loss (ii) Income Tax relating to items that will not be reclassified to Profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to Profit or loss	(2.64)	2.26	1.90	1.78	1.75
XV	<b>Total Comprehensive Income for the period (XIII + XIV) (Comprising profit/(Loss) and other comprehensive income for the period)</b>	<b>77.68</b>	<b>18.46</b>	<b>115.13</b>	<b>116.44</b>	<b>162.31</b>




XVI	Paid-up Share Capital of the Company (Face Value Rs 10/-)	374.70	374.70	374.70	374.70	374.70
XVII	Reserves Excluding Revaluation Reserves				3163.54	3055.88
XVIII	Earnings Per Share (for continuing operations)					
	(a) Basic	2.14	0.43	2.97	3.06	4.33
	(b) Diluted	2.14	0.43	2.97	3.06	4.33
XIX	Earnings Per Share (for Discontinued operations)					
	(a) Basic	-	-	-	-	-
	(b) Diluted	-	-	-	-	-
XX	Earnings Per Share (for Discontinued and continuing operations)					
	(a) Basic	2.14	0.43	2.97	3.06	4.33
	(b) Diluted	2.14	0.43	2.97	3.06	4.33

**Note :-**

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 27<sup>th</sup> May, 2019.
- The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] as amended and accordingly these financial results have been prepared in accordance with the recognition and measurement principals laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under.
- The company operates in two segments i.e. solvent extraction and commodities derivative trading. However, for the current quarter as well as corresponding quarter in previous year there is no requirement of segmental reporting as the sales of commodities/derivatives are less than the threshold limits.
- The Statutory Auditors of the company have carried out Audit of the Books of Account for the Financial Year 2018-19 and issued us an Audit Report with Unmodified Opinion on Audited Financial Results for the Quarter/Year ended 31.03.2019, therefore the company is not required to give Statement of Impact of Audit Qualification for Audit Report with Modified Opinion.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- Excise Duty on Sales was included under Revenue from operations and disclosed separately under Expenses up to all reporting periods ending 30<sup>th</sup> June, 2017. However, after implementation of Goods and Service Tax (GST) from 1<sup>st</sup> July, 2017, this is no longer relevant.
- Effective from 1<sup>st</sup> April, 2018, the company has adopted IND AS 115 "Revenue from Contract with Customers". Based on the assessment done by the management, there is no material impact on the revenue recognized during the period.
- The MCA wide notification dated 11<sup>th</sup> October, 2018 has amended Schedule III to the companies Act, 2013 in respect of certain disclosures. The company has incorporated appropriate changes in the above results.


Date: 27.05.2019  
Place: Itarsi



For, NATRAJ PROTEINS LTD.


**KAILASH CHAND SHARMA**  
Chairman & Managing Director  
DIN: 00012900

Statement of Assets and Liabilities		(Rupees in Lakhs)	
Particulars	Note No.	Figures as at the end of current reporting period 31/03/2019	Figures as at the end of previous reporting period 31/03/2018
1	2	3	4
		Audited	Audited
<b>ASSETS</b>			
<b>(1) Non-Current Assets</b>			
(a) Property, Plant and Equipment		353.59	370.88
(b) Capital Work-in-Progress		-	-
(c) Investment Property		-	-
(d) Goodwill		-	-
(e) Other Intangible assets		-	-
(f) Intangible assets under development		-	-
(g) Biological Assets other than bearer plants		-	-
(h) Financial Assets			
i. Investments		91.70	54.62
ii. Trade receivables		-	-
iii. Loans		-	-
iv. Others (to be specified)		-	-
(i) Deferred tax assets(net)		-	-
(j) Other non-current assets		162.94	397.63
<b>Total Non-Current Assets</b>		<b>608.23</b>	<b>823.13</b>
<b>(2) Current Assets</b>			
(a) Inventories		4113.99	8138.51
(b) Financial Assets			
i. Investments		-	-
ii. Trade receivables		1984.51	1432.63
iii. Cash and cash equivalents		6.37	3.79
iv. Bank balances other than (iii) above		405.49	34.87
v. Loans		105.00	139.32
vi. Other (to be specified)		-	-
(c) Current Tax Assets (Net)		0.67	27.50
(d) Other current assets		-	-
<b>Total Current Assets</b>		<b>6616.03</b>	<b>9776.62</b>
<b>Total Assets</b>		<b>7224.26</b>	<b>10599.75</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
(a) Equity Share Capital		374.70	374.70
(b) Other Equity		3163.54	3055.88
<b>LIABILITIES</b>			
<b>(1) Non-current liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings		-	-
(ii) Trade payables			
- Total outstanding dues of Micro and small enterprises;		-	-
- Total outstanding dues of creditors other than Micro and small enterprises;		-	-
(iii) Other Financial liabilities (other than those specified in item (b), to be specified)		5.00	7.50
(b) Provisions		-	-
(c) Deferred tax liabilities (Net)		92.90	100.08
(d) Other non-current liabilities		-	-
<b>Total Non-Current Liabilities</b>		<b>97.90</b>	<b>107.58</b>
<b>(2) Current liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings		3082.22	5410.39



(ii) Trade payables			
- Total outstanding dues of Micro and small enterprises;		0.00	4.29
- Total outstanding dues of creditors other than Micro and small enterprises;		392.91	1504.50
(iii) Other Financial liabilities (other than those specified in item (c))			
(b) Other current liabilities		112.59	128.94
(c) Provisions		0.40	13.48
(d) Current Tax Liabilities (Net)			
<b>Total Current Liabilities</b>		<b>3588.12</b>	<b>7061.59</b>
<b>Total Equity and Liabilities</b>		<b>7224.26</b>	<b>10599.75</b>

Date: 27.05.2019  
Place: Itarsi



For, NATRAJ PROTEINS LTD.

**KAILASH CHAND SHARMA**  
Chairman & Managing Director  
DIN: 000129405

# Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY  
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090

**Natraj**

Ref. :

Date :

NPL/SE/2019

27<sup>th</sup> May, 2019

Online filing at [www.listing.bseindia.com](http://www.listing.bseindia.com)

To,  
The General Manager  
DCS-CRD  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
MUMBAI - 400001

**BSE CODE: 530119**

**Sub.: Submission of declaration as per Second proviso to the Regulation 33(3) of the SEBI (LODR) Regulation, 2015 for the Annual Audited Financial Results for the year ended 31<sup>st</sup> March, 2019.**

Dear Sir/Ma'am,


We hereby submit the following declaration regarding unmodified Auditors Report on the Audited Financial Results/Statements for the year 31<sup>st</sup> March, 2019 as audited by the Auditors of the Company.


## DECLARATION

Pursuant to SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, and Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated 25<sup>th</sup> May, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated 27<sup>th</sup> May, 2016 and Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 issued by the SEBI, We, the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of the Company for the financial year ended on 31<sup>st</sup> March, 2019, the Auditor has not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the statement on impact of audit qualifications is not required to be given.

You are requested to please consider and take on record the same.

Thanking you,  
Yours faithfully,  
For, NATARJ PROTEINS LIMITED



  
KAILASH CHAND SHARMA  
CHAIRMAN & MANAGING DIRECTOR  
DIN: 00012900

  
RITESH SHARMA  
CHIEF FINANCIAL OFFICER